A series of triterpene compounds characterized by a stringent structure-activity relationship were identified as potent and selective inhibitors of human immunodeficiency virus type 1 (HIV-1) replication. Currently studied betulinic derivatives have 50% inhibitory concentrations (ICss) agaeHIV-1 strain III/LAI in the 10 nM range in several cellular infection assays but are inactive against HIV-2. These compounds did not significantly inhibit the in vitro activities of several purified HIV-l enzymes. Rather, they ap ed to block virus infection at a postbinding, envelope-dependent step involved in the fusion of the virus to the cell membrane. CCID5o) and cultured for 5 days. Cell viability was assessed by the spectrophotometric 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium-based assay (9). Mock-infected cultures were carried out in parallel to determine the degree of cytotoxicity of the compounds. p24 core antigen in culture supernatants was determined by ELISA (NEK060B kit from New England Nuclear). RT activity was measured by a poly(rA) 3H SPA scintillation proximity assay (NK9020 from Amersham). The antiviral assay using MT4 cells was as described (10) . The effect of compounds on the kinetics of viral production in human peripheral blood mononuclear cells (PBMCs) was also assayed. PBMCs from seronegative donors were isolated by Ficoll/Hypaque (Pharmacia) and stimulated for 3 days with phytohemagglutinin (2.5 pg/ml; Difco). Cells were then washed three times with medium, pelleted, and incubated with 50-100 CCID50 of virus stock per ml. After 1 hr at room temperature, cells were resuspended in RPMI 1640 medium containing 10%6 fetal bovine serum, 10%6 T-cell growth factors (Lymphocult, Biotest Diagnostics, Danville, NJ), and anti-interferon a neutralizing antibody (Bayer, Wuppertal, F.R.G.) at 80 units/ml. Cells were plated at 106 per ml in six-well culture plates (Costar) in the presence of the compound to be tested. At 3, 7, 10, and 14 days after infection, cultures were harvested and viable cells were examined by trypan blue exclusion. Aliquots of supernatants were frozen at -700C until tested for p24 antigen, and cells were resuspended at the same density in complete fresh medium with the same concentration of the tested drug.
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A survey of the agents that have been described to have activity against human immunodeficiency virus (HIV) reveals that only a limited number of the potential viral targets have been tackled, the most prominent being reverse transcriptase (RT) and protease (1) (2) (3) (4) . In particular, the designing and screening of agents that inhibit virus entry into cells have met with limited success. Despite high initial hopes, several candidate antagonists based on soluble CD4 have failed either in vitro or in vivo (5, 6) . On the other hand, polyanionic compounds that interfere with virus binding or penetration, in particular sulfated polymers, are likely to be ineffective because their specificity and bioavailability are poor (7) . Here we report on a class of hemisynthetic compounds derived from a natural triterpene which is targeted at HIV-1 entry into cells. CCID5o) and cultured for 5 days. Cell viability was assessed by the spectrophotometric 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium-based assay (9) . Mock-infected cultures were carried out in parallel to determine the degree of cytotoxicity of the compounds. p24 core antigen in culture supernatants was determined by ELISA (NEK060B kit from New England Nuclear). RT activity was measured by a poly(rA) 3H SPA scintillation proximity assay (NK9020 from Amersham). The antiviral assay using MT4 cells was as described (10) . The effect of compounds on the kinetics of viral production in human peripheral blood mononuclear cells (PBMCs) was also assayed. PBMCs from seronegative donors were isolated by Ficoll/Hypaque (Pharmacia) and stimulated for 3 days with phytohemagglutinin (2.5 pg/ml; Difco). Cells were then washed three times with medium, pelleted, and incubated with 50-100 CCID50 of virus stock per ml. After 1 protocol (11) . A 152-bp fragment of the gag gene of HIV-1 and a 237-bp segment of the mitochondrial cytochrome b gene as a control were amplified by PCR. The absence of nuclear genomic DNA was checked on a 336-bp fragment of the (3-globin gene. PCR products were visualized directly by fluorescence after electrophoresis in a 3% NuSieve agarose gel (FMC) and by autoradiography after transfer and hybridization with specific internal oligonucleotide probes. Amplification products were quantitated with a digital autoradiography detector (Packard), and the percentage of proviral DNA was estimated by taking the ratio of HIV-1 gag product to cytochrome b product and comparing it with that obtained from untreated control cells. 3'-Azido-3'-deoxythymidine (AZT) was used as a reference compound.
MATERIALS AND METHODS
Assays of Viral Enzymes. In the exogenous RT assay (12), the reaction mixture (50 tl) contained 50 mM Tris-HCl (pH 8.4), 10 mM MgCl2, 100 mM KCl, 2.2 mM dithiothreitol, 2.5 ,uM dGTP, and 0.05% (wt/vol) Triton X-100. The template poly(C) or poly(dC) and the primer (dG)12_18 (Pharmacia) were used at concentrations of 40 and 6 pg/ml, respectively.
Recombinant HIV-1 RT was used at 1 nM. HIV-1 integrase assays were carried out essentially as described (13) . In brief, reaction mixtures containing 20 mM Hepes (pH 7.0), 10 mM MnCl2, 50 mM NaCl, 10% (vol/vol) glycerol, 10 mM dithiothreitol, bovine serum albumin at 0.1 mg/mi, 0.5 pmol of 32P-labeled HIV-1 U5-end oligonucleotide substrate, and 5 pmol of purified recombinant HIV-1 integrase (14) were incubated at 30°C for 1 hr. Autointegration products were visualized and quantified by autoradiography after electrophoresis in a 20%o polyacrylamide DNA-sequencing gel. For another protocol, 15 ng of plasmid DNA (3 kb) was included in the reaction mixture as a heterologous integration target: in this case, a 1.2% agarose gel was used (15) . The assay for HIV-1 protease inhibition was as described (16) .
Time-of-Addition Experiment. Delineation of the drugsensitive phase was determined with MT-4 cells infected at a high multiplicity of infection, >1, with HIV-1 strain IIIB. Compounds were added, at a concentration 50-fold to 100-fold higher than their IC50 value in the standard MT-4/3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium assay, to parallel cultures (37°C) in microtiter plates at the indicated time after the addition of virus to the cells. After the last addition, all cells were washed to remove unbound virus, resuspended in the same concentration of compound, and further incubated for 24 hr. HIV-1 p24 core protein was then quantitated by a sandwich ELISA (DuPont).
Virus Binding and Syncytium Formation. The interaction between recombinant soluble CD4 (sCD4) (a gift from D. Klatzmann, H6pital de la Pitid, Paris) and HIV-1 envelope glycoprotein gp120 (Repligen) was analyzed with either a CD4-gpl2O ELISA kit (DuPont) or the recently developed biosensor technology (BIAcore, Pharmacia) (17) . The binding of HIV-1 virion particles to CD4+ cells (CEM) was evaluated by flow cytometry (18) on an ATC 3000 fluorescence-activated cell sorter (ODAM, Wissembourg, France) with anti-gp120 (NEA 9301, DuPont) or anti-CD4 (OKT4, Ortho Diagnostics) monoclonal antibodies. The binding of these mouse monoclonal antibodies was revealed with a fluorescein-conjugated goat anti-mouse IgG antibody (Immunotech, Luminy, France). In these experiments, aurintricarboxylic acid or sCD4 was used as reference compound and AZT as a negative control. The inhibition of syncytium formation was quantified by using a HeLa CD4+ LTR (long terminal repeat)-lacZ indicator cell line, called P4. The cytoplasm of these cells turns blue upon treatment after infection by cell-free virus or after fusion with cells expressing HIV-1 Env and Tat proteins (19, 20) . In brief, indicator cells (104 per well) were incubated for 24 hr in a microtiter plate, and pretreated for 1 hr at the desired concentration of compound. H9/IIIB chronically infected cells or HL2/3 cells, harboring a defective provirus but expressing high levels of HIV-1 proteins (21), were then added (5 x 103 per well) in the presence ofthe drug. After 24 hr at 37°C, cells were washed, fixed in 1% formaldehyde/0.2% glutaraldehyde for 5 min, washed again, and incubated in with 5-bromo-4-chloro-3-indolyl (-D-galactopyranoside as described (20 RESULTS AND DISCUSSION Certain amide derivatives of betulinic acid, a triterpene extracted from plane tree bark (Fig. 1) , were initially found to be modest inhibitors of both HIV-1 protease in vitro and HIV-1 infection in cellular assays. However, in the course of examining compounds having subsequent chemical modifications, we unexpectedly detected a derivative bearing an 11-aminoundecanoic lateral chain (RP70034; Fig. 1 assays (ICso 0.3 ,uM) than the original compounds. Structure-activity relationships for this series of derivatives suggested a rather stringent specificity. In particular, analogous derivatives of other tested natural triterpenes were inactive, an optimal length ofthe lateral chain was needed, and several positions on the molecule could not be modified, even slightly, without significant loss of activity (unpublished work). Chemical optimization of the lateral chain resulted in more potent compounds, represented by RPR 103611 (Figs.  1 and 2B) , the mechanism of which was further studied.
The effect of betulinic derivatives in cellular infection assays is shown in Fig. 2 . Efficient protection from the virus-induced cytopathic effect was observed in various cell lines. Similar efficiencies were observed with CEM cells, for which an important single-cell killing component is usually observed (9, 24) , and with MT-4 cells transfected with 10 proviral DNA of human T-lymphocytic virus type I, where the formation of syncytia contributes to the development of the cytopathic effect (10). Indeed, this effect is accompanied by a suppression of virus production, measured either as RT activity or as the concentration of p24 antigen in the culture supernatant ( Fig. 2A) . We also checked the activity of the compounds in several other cell lines, including the monocytic cell line U-937, and in peripheral blood lymphocytes (Table 1 (Fig. 2B) . Evidence that the specificity for these compounds could be restricted even within the HIV-1 family was supplied by the observation that most compounds active against IUB/LAI were not active, or much less active, against two isolates of Zairian origin, NDK and ELI (Table 1) . Thus, betulinic derivatives apparently interfere with a very specific molecular event of the replication cycle. corresponds to the ratio CCso/ICso, where CC5o is the 50%6 cytotoxic concentration for mock-infected cells. In the case of LAI in PBMCs, the lowest tested concentration was 0.1 pM and gave >50% inhibition.
Active derivatives were also examined for a possible inhibition of the in vitro activity of several purified HIV-1 enzymes. No inhibition of RT, integrase, or protease was detected at concentrations ofthe derivatives compatible with cellular activity (data not shown), suggesting that the corresponding steps were not involved in the inhibitory mechanism of these compounds. In fact, evidence was obtained from two different experiments that betulinic derivatives act at an early stage in the infectious cycle. First, we observed a clear dose-dependent inhibitory effect of compounds at micromolar concentrations on the synthesis of proviral cytoplasmic DNA, as measured by PCR only 2 hr after the onset of infection (data not shown). Second, we studied the influence of delaying the addition of compounds at various times soon after the exposure of MT-4 cells to HIV-1. Such an experiment showed (Fig. 3A) that postponing the addition of RPR 103611 for 1 hr was enough to cancel the inhibitory potency of this compound on the subsequent production of viral antigens. Betulinic derivatives behaved in this particular experiment very similarly to agents that interfere with the binding of virus to cells, such as sulfated polysaccharides, or to compounds proposed to interact with a viral uncoating event, such as bicyclams (25) . In fact, that the betulinic derivatives affect virus binding was ruled out by several experiments showing that betulinic derivatives did not significantly inhibit either the binding of the virus to CD4 cells (Fig. 4A) or the binding of sCD4 to gpl20 (Fig. 4B) . Proof for the mechanism of action came from assays designed to monitor syncytium formation between uninfected CD4 cells and chronically HIV-1-infected cells or cells expressing the HIV-1 envelope. Betulinic derivatives efficiently blocked the formation of syncytia induced by HIV-1 strain IIIB (Fig. 3B) but not the formation ofgiant cells induced by the NDK strain (R.P., unpublished data; the lack of activity in HIV-1 strain NDK-dependent syncytia assays correlates well with the inefficacy of this compound against the NDK isolate in A .o cellular infection assays). More specific syncytium assays were carried out by using recombinant vaccinia viruses expressing either the normal envelope from strain HIV-1 LAI or an uncleavable mutant gpl60 protein (23) . Active betulinic derivatives at submicromolar concentrations inhibited the envelope-dependent syncytium formation but did not block the formation of aggregates observed when the envelope variant was used (data not shown). Finally, the compounds at active concentrations did not exert a direct viricidal effect, since preincubation of the virus with the compounds did not modify its subsequent infective capacity. Together, these results provide evidence that the betulinic derivatives studied block virus infection at a postbinding step necessary for virus-membrane fusion and that the target of these compounds is contained within, or interacts with, the HIV-1 envelope gpl20/gp4l. This is, to our knowledge, the first description of a nonpeptidic compound having this potential, since, until now, only monoclonal antibodies or peptides have been shown to selectively affect the HIV-1 membrane fusion step (27, 28) . However, drugs that block fusion events induced by certain myxoviruses have been described-for example, amantadine in the case of influenza A (reviewed in ref. 29) .
Unlike the relatively well-known gp12O-CD4 binding, the postbinding molecular events leading to HIV-1 envelopemediated membrane fusion are much less well understood but are likely to be characterized by major conformational changes of the whole gpl20/gp4l complex, ultimately resulting in the productive exposure of the gp4l N-terminal fusogenic domain. This mechanism is important not only for the penetration of free virus into cells but also for cell fusion processes that can lead to syncytium formation, an important determinant of in vitro cytopathogenicity, as well as cell-tocell viral dissemination (30, 31) . Studies have mapped elements of the gpl20 and gp4l glycoproteins essential for efficient membrane fusion (32) ; it will be important to determine which of these peptides is affected by the inhibitory mechanism of betulinic acid derivatives. Because of their mode of action, the potential clinical usefulness of these agents in treating HIV-1 disease deserves further investigation.
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